{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:54:52Z","timestamp":1785412492027,"version":"3.56.0"},"reference-count":48,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key R&D Program of Shandong Province, China","award":["2024CXPT029"],"award-info":[{"award-number":["2024CXPT029"]}]},{"name":"Key R&D Program of Shandong Province, China","award":["2025CXPT011"],"award-info":[{"award-number":["2025CXPT011"]}]},{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2024QH615"],"award-info":[{"award-number":["ZR2024QH615"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"award":["ZR2024QH615"],"award-info":[{"award-number":["ZR2024QH615"]}],"id":[{"id":"https:\/\/ror.org\/04aqat463","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Shandong Laboratory Program","award":["SYS202205"],"award-info":[{"award-number":["SYS202205"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82104140"],"award-info":[{"award-number":["82104140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"award":["82104140"],"award-info":[{"award-number":["82104140"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Parkinson\u2019s disease (PD) is pathologically characterized by the abnormal aggregation of \u03b1-synuclein and the progressive loss of dopaminergic neurons, with microglia-mediated neuroinflammation acting as a pivotal driver of pathogenesis. Ferroptosis, an iron-dependent form of regulated cell death, significantly contributes to PD progression. However, the precise mechanisms governing microglial ferroptosis under \u03b1-synuclein pathology, particularly the regulatory role of the master antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2), remain elusive. Here, we employed an in vitro BV2 microglial model and an in vivo A53T transgenic mouse model to elucidate the regulatory effects and underlying mechanisms of Nrf2 on ferroptosis-associated phenotypes induced by \u03b1-synuclein pre-formed fibrils (PFFs). In vitro, PFF treatment significantly downregulated microglial Nrf2 expression, triggering ferroptosis-associated phenotypes characterized by reactive oxygen species (ROS) accumulation, ferrous iron (Fe2+) overload, and elevated lipid peroxidation. Genetic knockdown of Nrf2 exacerbated these ferroptosis-associated phenotypes and accelerated \u03b1-synuclein aggregation. Conversely, Nrf2 overexpression or pharmacological activation via dimethyl fumarate (DMF) profoundly suppressed \u03b1-synuclein pathology and mitigated ferroptosis-associated signatures. In vivo, microglial activation in the substantia nigra of PD mice was accompanied by marked Nrf2 downregulation. Strikingly, microglia-specific Nrf2 overexpression significantly reversed motor and non-motor deficits (including olfactory and locomotor impairments), demonstrating the sufficiency of microglial protection. Furthermore, systemic administration of the Nrf2 activator DMF not only ameliorated motor dysfunction but also concurrently rescued nigral dopaminergic neurons and reduced striatal \u03b1-synuclein aggregation. Taken together, our findings identify Nrf2 downregulation-driven microglial ferroptosis-associated phenotypes as a critical pathogenic mechanism, and demonstrate that targeting this pathway in vivo ameliorates motor and non-motor deficits while preserving dopaminergic neurons in PD mice. These findings support further research on Nrf2 activation and DMF as potential therapeutic strategies for PD.<\/jats:p>","DOI":"10.3390\/ijms27104579","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:30:51Z","timestamp":1779280251000},"page":"4579","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microglial Nrf2 Activation Orchestrates Ferroptosis Inhibition and \u03b1-Synuclein Clearance in Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"27","author":[{"given":"Feifan","family":"Chen","sequence":"first","affiliation":[{"name":"Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China"},{"name":"Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingneng","family":"Liang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China"},{"name":"Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Guo","sequence":"additional","affiliation":[{"name":"Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China"},{"name":"Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-4351","authenticated-orcid":false,"given":"Hongchun","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Geng","sequence":"additional","affiliation":[{"name":"Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China"},{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Marine Drugs, Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China"},{"name":"Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China"},{"name":"State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13024-020-00408-1","article-title":"Glycosphingolipids and neuroinflammation in Parkinson\u2019s disease","volume":"15","author":"Belarbi","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","article-title":"Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms","volume":"8","author":"Block","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.4049\/jimmunol.1000208","article-title":"Paroxetine Prevents Loss of Nigrostriatal Dopaminergic Neurons by Inhibiting Brain Inflammation and Oxidative Stress in an Experimental Model of Parkinson\u2019s Disease","volume":"185","author":"Chung","year":"2010","journal-title":"J. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: Molecular mechanisms and health implications","volume":"31","author":"Tang","year":"2021","journal-title":"Cell Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102477","DOI":"10.1016\/j.arr.2024.102477","article-title":"Ferroptosis in Parkinson\u2019s disease\u2014The iron-related degenerative disease","volume":"101","author":"Yao","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2017.04.005","article-title":"Targeting Free Radicals in Oxidative Stress-Related Human Diseases","volume":"38","author":"Poprac","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.freeradbiomed.2020.03.015","article-title":"Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson\u2019s disease","volume":"152","author":"Zhang","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1074\/jbc.M409946200","article-title":"Metal-catalyzed oxidation of alpha-synuclein: Helping to define the relationship between oligomers, protofibrils, and filaments","volume":"280","author":"Cole","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16116","DOI":"10.1074\/jbc.M107866200","article-title":"Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein","volume":"277","author":"Golts","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0891-0618(00)00096-X","article-title":"Crosslinking of alpha-synuclein by advanced glycation endproducts\u2014An early pathophysiological step in Lewy body formation?","volume":"20","author":"Wong","year":"2000","journal-title":"J. Chem. Neuroanat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"44284","DOI":"10.1074\/jbc.M105343200","article-title":"Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson\u2019s disease and heavy metal exposure","volume":"276","author":"Uversky","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","article-title":"Role of nrf2 in oxidative stress and toxicity","volume":"53","author":"Ma","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_15","first-page":"9372182","article-title":"Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development","volume":"2019","author":"Manda","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.14336\/AD.2018.0513","article-title":"The Anti-Inflammatory and Anti-Oxidant Mechanisms of the Keap1\/Nrf2\/ARE Signaling Pathway in Chronic Diseases","volume":"10","author":"Tu","year":"2019","journal-title":"Aging Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJMoa1809983","article-title":"Randomized Delayed-Start Trial of Levodopa in Parkinson\u2019s Disease","volume":"380","author":"Verschuur","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.5b00410","article-title":"Synthesis of piperlongumine analogues and discovery of nuclear factor erythroid 2-related factor 2 (Nrf2) activators as potential neuroprotective agents","volume":"58","author":"Peng","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102861","DOI":"10.1016\/j.msard.2021.102861","article-title":"A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: Evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers","volume":"51","author":"Edwards","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuroscience.2014.11.018","article-title":"M1 and M2 immune activation in Parkinson\u2019s Disease: Foe and ally?","volume":"302","author":"Moehle","year":"2015","journal-title":"Neuroscience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/0113894501320839240918110656","article-title":"Nrf2 and Ferroptosis: Exploring Translational Avenues for Therapeutic Approaches to Neurological Diseases","volume":"26","author":"Mohan","year":"2025","journal-title":"Curr. Drug Targets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41531-025-00912-5","article-title":"Voluntary exercise alleviates neural functional deficits in Parkinson\u2019s disease mice by inhibiting microglial ferroptosis via SLC7A11\/ALOX12 axis","volume":"11","author":"Xu","year":"2025","journal-title":"npj Park. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-020-03369-x","article-title":"Intranasal administration of \u03b1-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis","volume":"12","author":"Guo","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110358","DOI":"10.1016\/j.celrep.2022.110358","article-title":"Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological \u03b1-synuclein","volume":"38","author":"Sterling","year":"2022","journal-title":"Cell Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41593-022-01221-3","article-title":"Microglia ferroptosis is regulated by SEC24B and contributes to neurodegeneration","volume":"26","author":"Ryan","year":"2023","journal-title":"Nat. Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.nbd.2015.03.003","article-title":"Glia and alpha-synuclein in neurodegeneration: A complex interaction","volume":"85","author":"Wenning","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/brain\/awaa090","article-title":"Microglial exosomes facilitate \u03b1-synuclein transmission in Parkinson\u2019s disease","volume":"143","author":"Guo","year":"2020","journal-title":"Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13024-019-0335-3","article-title":"Microglia affect \u03b1-synuclein cell-to-cell transfer in a mouse model of Parkinson\u2019s disease","volume":"14","author":"George","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2413451","DOI":"10.1002\/advs.202413451","article-title":"Microglia Process \u03b1-Synuclein Fibrils and Enhance their Pathogenicity in a TREM2-Dependent Manner","volume":"12","author":"Xiong","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Li, L.A.-O., Liu, X., Si, Z., and Wang, X.A.-O. (2025). Epigenetic Mechanisms Governing Nrf2 Expression and Its Role in Ferroptosis. Biomedicines, 13.","DOI":"10.3390\/biomedicines13081913"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4049\/jimmunol.181.1.680","article-title":"The transcription factor Nrf2 is a therapeutic target against brain inflammation","volume":"181","author":"Innamorato","year":"2008","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/glia.20947","article-title":"Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson\u2019s disease","volume":"58","author":"Rojo","year":"2010","journal-title":"Glia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1089\/ars.2010.3731","article-title":"Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism","volume":"14","author":"Jazwa","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lee, K.H., Cha, M., and Lee, B.A.-O. (2020). Neuroprotective Effect of Antioxidants in the Brain. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197152"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.freeradbiomed.2019.01.016","article-title":"Redox regulation by NRF2 in aging and disease","volume":"134","author":"Schmidlin","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/nen.0b013e31802d6da9","article-title":"Expression of Nrf2 in neurodegenerative diseases","volume":"66","author":"Ramsey","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1093\/hmg\/dds143","article-title":"\u03b1-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson\u2019s disease","volume":"21","author":"Ulusoy","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1196\/annals.1427.036","article-title":"The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration","volume":"1147","author":"Johnson","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuroscience.2014.11.047","article-title":"Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson\u2019s disease by enhancing Nrf2 activity","volume":"286","author":"Jing","year":"2015","journal-title":"Neuroscience"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Brandes, M.S., Zweig, J.A., Tang, A., and Gray, N.E. (2022). NRF2 Activation Ameliorates Oxidative Stress and Improves Mitochondrial Function and Synaptic Plasticity, and in A53T \u03b1-Synuclein Hippocampal Neurons. Antioxidants, 11.","DOI":"10.3390\/antiox11010026"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/ars.2015.6549","article-title":"Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson\u2019s Disease","volume":"25","author":"Scannevin","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10571-021-01131-1","article-title":"Apomorphine Reduces A53T \u03b1-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway","volume":"42","author":"Heurtaux","year":"2021","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"25009","DOI":"10.1074\/jbc.M300227200","article-title":"Alpha-Synuclein is degraded by both autophagy and the proteasome","volume":"278","author":"Webb","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.redox.2017.01.006","article-title":"Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases","volume":"11","author":"Pajares","year":"2017","journal-title":"Redox Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e12948","DOI":"10.1111\/jpi.12948","article-title":"Melatonin MT1 receptors regulate the Sirt1\/Nrf2\/Ho-1\/Gpx4 pathway to prevent \u03b1-synuclein-induced ferroptosis in Parkinson\u2019s disease","volume":"76","author":"Lv","year":"2024","journal-title":"J. Pineal Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1007\/s10753-025-02291-8","article-title":"LRRK2 Mediates \u03b1-Synuclein-Induced Neuroinflammation and Ferroptosis through the p62-Keap1-Nrf2 Pathway in Parkinson\u2019s Disease","volume":"48","author":"Liu","year":"2025","journal-title":"Inflammation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/nprot.2014.143","article-title":"Addition of exogenous \u03b1-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous \u03b1-synuclein to Lewy body and Lewy neurite-like aggregates","volume":"9","author":"Luk","year":"2014","journal-title":"Nat. Protoc."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4579\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:28:14Z","timestamp":1779424094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27104579"],"URL":"https:\/\/doi.org\/10.3390\/ijms27104579","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]}}}